Cargando…
The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection
Stabilized HIV-1 envelope (Env) trimers elicit tier 2 autologous neutralizing antibody (nAb) responses in immunized animals. We previously demonstrated that BG505 SOSIP.664.T332N gp140 (BG505 SOSIP) immunization of rhesus macaques (RM) provided robust protection against autologous intra-vaginal simi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895394/ https://www.ncbi.nlm.nih.gov/pubmed/33556148 http://dx.doi.org/10.1371/journal.ppat.1009257 |
_version_ | 1783653355851087872 |
---|---|
author | Charles, Tysheena P. Burton, Samantha L. Arunachalam, Prabhu S. Cottrell, Christopher A. Sewall, Leigh M. Bollimpelli, Venkata S. Gangadhara, Sailaja Dey, Antu K. Ward, Andrew B. Shaw, George M. Hunter, Eric Amara, Rama R. Pulendran, Bali van Gils, Marit J. Derdeyn, Cynthia A. |
author_facet | Charles, Tysheena P. Burton, Samantha L. Arunachalam, Prabhu S. Cottrell, Christopher A. Sewall, Leigh M. Bollimpelli, Venkata S. Gangadhara, Sailaja Dey, Antu K. Ward, Andrew B. Shaw, George M. Hunter, Eric Amara, Rama R. Pulendran, Bali van Gils, Marit J. Derdeyn, Cynthia A. |
author_sort | Charles, Tysheena P. |
collection | PubMed |
description | Stabilized HIV-1 envelope (Env) trimers elicit tier 2 autologous neutralizing antibody (nAb) responses in immunized animals. We previously demonstrated that BG505 SOSIP.664.T332N gp140 (BG505 SOSIP) immunization of rhesus macaques (RM) provided robust protection against autologous intra-vaginal simian-human immunodeficiency virus (SHIV) challenge that was predicted by high serum nAb titers. Here, we show that nAb in these protected RM targeted a glycan hole proximal to residue 465 in gp120 in all cases. nAb also targeted another glycan hole at residues 241/289 and an epitope in V1 at varying frequencies. Non-neutralizing antibodies directed at N611-shielded epitopes in gp41 were also present but were more prevalent in RM with low nAb titers. Longitudinal analysis demonstrated that nAb broadened in some RM during sequential immunization but remained focused in others, the latter being associated with increases in nAb titer. Thirty-eight monoclonal antibodies (mAbs) isolated from a protected RM with an exceptionally high serum neutralization titer bound to the trimer in ELISA, and four of the mAbs potently neutralized the BG505 Env pseudovirus (PV) and SHIV. The four neutralizing mAbs were clonally related and targeted the 465 glycan hole to varying degrees, mimicking the serum. The data demonstrate that the C3/465 glycan hole cluster was the dominant neutralization target in high titer protected RM, despite other co-circulating neutralizing and non-neutralizing specificities. The isolation of a neutralizing mAb family argues that clonotype expansion occurred during BG505 SOSIP immunization, leading to high titer, protective nAb and setting a desirable benchmark for HIV vaccines. |
format | Online Article Text |
id | pubmed-7895394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-78953942021-03-01 The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection Charles, Tysheena P. Burton, Samantha L. Arunachalam, Prabhu S. Cottrell, Christopher A. Sewall, Leigh M. Bollimpelli, Venkata S. Gangadhara, Sailaja Dey, Antu K. Ward, Andrew B. Shaw, George M. Hunter, Eric Amara, Rama R. Pulendran, Bali van Gils, Marit J. Derdeyn, Cynthia A. PLoS Pathog Research Article Stabilized HIV-1 envelope (Env) trimers elicit tier 2 autologous neutralizing antibody (nAb) responses in immunized animals. We previously demonstrated that BG505 SOSIP.664.T332N gp140 (BG505 SOSIP) immunization of rhesus macaques (RM) provided robust protection against autologous intra-vaginal simian-human immunodeficiency virus (SHIV) challenge that was predicted by high serum nAb titers. Here, we show that nAb in these protected RM targeted a glycan hole proximal to residue 465 in gp120 in all cases. nAb also targeted another glycan hole at residues 241/289 and an epitope in V1 at varying frequencies. Non-neutralizing antibodies directed at N611-shielded epitopes in gp41 were also present but were more prevalent in RM with low nAb titers. Longitudinal analysis demonstrated that nAb broadened in some RM during sequential immunization but remained focused in others, the latter being associated with increases in nAb titer. Thirty-eight monoclonal antibodies (mAbs) isolated from a protected RM with an exceptionally high serum neutralization titer bound to the trimer in ELISA, and four of the mAbs potently neutralized the BG505 Env pseudovirus (PV) and SHIV. The four neutralizing mAbs were clonally related and targeted the 465 glycan hole to varying degrees, mimicking the serum. The data demonstrate that the C3/465 glycan hole cluster was the dominant neutralization target in high titer protected RM, despite other co-circulating neutralizing and non-neutralizing specificities. The isolation of a neutralizing mAb family argues that clonotype expansion occurred during BG505 SOSIP immunization, leading to high titer, protective nAb and setting a desirable benchmark for HIV vaccines. Public Library of Science 2021-02-08 /pmc/articles/PMC7895394/ /pubmed/33556148 http://dx.doi.org/10.1371/journal.ppat.1009257 Text en © 2021 Charles et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Charles, Tysheena P. Burton, Samantha L. Arunachalam, Prabhu S. Cottrell, Christopher A. Sewall, Leigh M. Bollimpelli, Venkata S. Gangadhara, Sailaja Dey, Antu K. Ward, Andrew B. Shaw, George M. Hunter, Eric Amara, Rama R. Pulendran, Bali van Gils, Marit J. Derdeyn, Cynthia A. The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection |
title | The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection |
title_full | The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection |
title_fullStr | The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection |
title_full_unstemmed | The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection |
title_short | The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection |
title_sort | c3/465 glycan hole cluster in bg505 hiv-1 envelope is the major neutralizing target involved in preventing mucosal shiv infection |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895394/ https://www.ncbi.nlm.nih.gov/pubmed/33556148 http://dx.doi.org/10.1371/journal.ppat.1009257 |
work_keys_str_mv | AT charlestysheenap thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT burtonsamanthal thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT arunachalamprabhus thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT cottrellchristophera thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT sewallleighm thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT bollimpellivenkatas thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT gangadharasailaja thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT deyantuk thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT wardandrewb thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT shawgeorgem thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT huntereric thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT amararamar thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT pulendranbali thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT vangilsmaritj thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT derdeyncynthiaa thec3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT charlestysheenap c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT burtonsamanthal c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT arunachalamprabhus c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT cottrellchristophera c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT sewallleighm c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT bollimpellivenkatas c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT gangadharasailaja c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT deyantuk c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT wardandrewb c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT shawgeorgem c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT huntereric c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT amararamar c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT pulendranbali c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT vangilsmaritj c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection AT derdeyncynthiaa c3465glycanholeclusterinbg505hiv1envelopeisthemajorneutralizingtargetinvolvedinpreventingmucosalshivinfection |